`US 7,411,070 B2
`(0) Patent No.:
`*Aug. 12, 2008
`(45) Date of Patent:
`Cotton et al.
`
`US007411070B2
`
`(54) FORM OF S-OMEPRAZOLE
`
`(75)
`
`Inventors: [anna Cotton, Sédertalje (SE); Anders
`Kronstrém, Sédertiljc (SE); Anders
`Mattson, Sdédertalje (SE); Eva Miller,
`Sédertalje (SE)
`(73) Assignee: AstraZeneca AB, Sodertalje (SIesl)
`
`
`
`EP
`EP
`IN
`WO
`WoO
`WO
`WO
`
`0247983
`WO 95/01977
`1344/DEL/98
`9427988
`9501977
`9601623
`9602535
`
`*
`
`12/1987
`1/1995
`5/1998
`12/1994
`1/1995
`1/1996
`2/1996
`
`OTHER PUBLICATIONS
`
`(*) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21) Appl. No.: 10/672,936
`
`(22)
`
`Filed:
`
`Sep. 25, 2003
`
`(65)
`
`Prior Publication Data
`
`US 2005/0075369 Al
`
`Apr. 7, 2005
`
`Related U.S. Application Data
`
`Japanese Chemical Society, Experimental Chemical Seminar. vol.
`18. p. 55 (translation), 1958.*
`An Introduction to Crystal Chemistry by Evans Cambridge At the
`Univ. Press, 1914.*
`Erlandsson,P. Et al., “Resolution of the enantiomers of omeprazole
`and some of its analogues by liquid chromatography on a
`trisphenylcarbamoyl cellulose-based stationary phase”, Journal of
`Chromatography, 532 (1990) 305-319.
`von Unge,S. et al. “Stereochemical assignmentofthe enantiomers of
`omeprazole from X-ray analysis of a fenchyloxylmethyl derivative of
`(+)-(R)-omeprazole”, Tetrahedron Asymmetry, vol. 8, No. 12, pp.
`1967-1970 (1997).
`An Introduction to Crystal Chemistry by Evans Cambridge at the
`Univ. Press, 1964.
`Opposition filed by Ranbaxy Laboratories Limited against Indian
`Patent Application No. 1344/DEL/98.
`Opposition filed by Torrent Pharmaceuticals Limited against Indian
`Patent Application No. 1344/DEL/98.
`X-ray powder diffraction pattern of Mg-salt of S-omeprazole
`trihydrate depicted by Torrent obtained by method ofWO 94/27988.
`NDA 21-153/S-020 for Nexium® (esomeprazole magnesium)
`Delayed Release Capsule.
`NDA 21-153/21-154 entitled “Medical Review(s)”.
`Statement with Exhibits A-C on Behalfofthe Applicant, AstraZeneca
`May 30,1997=(SE) ee ceeceeerereeeeeteees 9702065
`AB,to the Opposition filed by Ranbaxy Laboratories Limited against
`Indian Patent Application No. 1344/DEL/98.
`the Applicant,
`Statement with Exhibits A-D on Behalf of
`AstraZeneca AB,to the Oppositionfiled by lorrent Pharmaceuticals
`Limited against Indian Patent Application No. 1344/DEL/98.
`Decision of the Pre-grant Opposition filed by Ranbaxy Laboratories
`Limited against Indian Patent Application No. 1344/DEL/98.
`Decision of the Pre-grant Opposition filed by Torrent Pharmaceuti-
`cals Limited against Indian Patent Application No. 1344/DEL/98.
`Notice of Allegation, dated Nov. 13, 2007, pursuant to the Patented
`Medicines (Notice ofCompliance) Regulations with respect to Cana-
`dian Letters Patent No. 2,290,963.
`
`(60) Continuation of application No. 10/076,711, filed on
`Feb. 14, 2002, now Pat. No. 6,677,455, which is a
`division of application No. 09/077,719, filed as appli-
`cation No. PCT/SE98/00974 on May 25, 1998, now
`Pat. No. 6,369,085.
`
`(30)
`
`Foreign Application Priority Data
`
`(51)
`
`Int. Cl.
`(2006.01)
`CO7D 401/12
`(2006.01)
`A61K 31/4439
`(52) US. Ch oe ee reeeeeeees 546/273.7; 514/338
`(58) Field of Classification Search ........0....... 514/338;
`546/273.7
`
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`.......... 424/263
`3/1981 Junggren etal.
`4,255,431 A
`4/1988 Brandstrom ............0. 514/338
`4,738,974 A *
`we 424/468
`11/1988 Lovgren et al.
`4,786,505 A
`
`6/1996 Nore etal. oc. 562/571
`5,530,160 A
`10/1997 Tiers etal. we 252/582
`5,676,884 A
`
`.... 514/338
`5,690,960 A * 11/1997 Bengtsson etal.
`
`5,693,818 A * 12/1997 Vion Unge........
`.... 514/338
`5,714,504 A *
`2/1998 Lindberg etal.
`..... we 514/338
`.......... 424/468
`5,817,338 A
`10/1998 Bergstrand et al.
`
`..... we 514/338
`5,877,192 A
`3/1999 Lindberg etal.
`
`.. 514/338
`5,900,424 A
`5/1999 Kallstrém et al.
`.
`4/2002 Cottonetal. ww. 514/338
`6,369,085 Bl
`1/2004 Kronstrom etal.
`6,677,455 B2
`6/2004 Kronstrom etal.
`6,747,155 B2
`
`FOREIGN PATENT DOCUMENTS
`
`CN
`DE
`EP
`EP
`
`1136564
`4035 455
`0005129
`0124495
`
`11/1996
`5/1992
`10/1979
`11/1984
`
`* cited by examiner
`
`Primary Examiner—Charanjit S Aulakh
`(74) Attorney, Agent, or Firm—White & Case LLP
`
`(57)
`
`ABSTRACT
`
`The present invention relates to a novel form of the (-)-
`enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-
`pyridinyl)-methy]|sulfinyl]-1 H-benzimidazole,
`i.e. S-ome-
`prazole. More specifically, it relates to a novel form of the
`magnesium salt of the S-enantiomer of omeprazole trihy-
`drate. The present invention also relates to processes for pre-
`paring such a form of the magnesium salt of S-omeprazole
`and pharmaceutical compositions containing it. Furthermore,
`the present inventionalso relates to newintermediates used in
`the process.
`
`4 Claims, 5 Drawing Sheets
`
`DRL EXHIBIT 1024 PAGE 1
`
`DRL EXHIBIT 1024 PAGE 1
`
`
`
`U.S. Patent
`
`Aug.12, 2008
`
`Sheet 1 of 5
`
`US 7,411,070 B2
`
`Ln
`~
`
`gyad
`
`o.
`
`xjN
`
`sy~
`
`NY
`
`2
`
`R
`
`i
`
`in
`N
`
`S
`N\
`
`22
`
`in
`
`~
`
`é
`
`=
`
`S s
`S 3
`~
`
`2
`
`S
`in
`
`>
`
`DRL EXHIBIT 1024 PAGE 2
`
`DRL EXHIBIT 1024 PAGE 2
`
`
`
`U.S. Patent
`
`Aug.12, 2008
`
`Sheet 2 of 5
`
`US 7,411,070 B2
`
`[2T]402-Theta~Scale
`
`30
`
`20
`
`10
`
`
`
`
`
`Lin(Coun#s)
`
`2000
`
`1500
`
`7000
`
`500
`
`DRL EXHIBIT 1024 PAGE 3
`
`DRL EXHIBIT 1024 PAGE 3
`
`
`
`U.S. Patent
`
`Aug.12, 2008
`
`Sheet 3 of 5
`
`US 7,411,070 B2
`
`wr
`rm
`
`SY
`
`3A'
`
`> aad
`meaay
`
`\N
`
`Ln
`N
`
`Sr
`
`e
`
`ww~~
`
`DD~~
`
`wn
`
`!
`
`tt
`
`Lin(Counts)
`
`2000
`
`1500
`
`1000
`
`500
`
`DRL EXHIBIT 1024 PAGE 4
`
`DRL EXHIBIT 1024 PAGE 4
`
`
`
`U.S. Patent
`
`Aug.12, 2008
`
`Sheet 4 of 5
`
`US 7,411,070 B2
`
`}
`
`
`
`30352-Thefta-Scale
`
`25
`
`20
`
`15
`
`10
`
` Lin(Counts)
`
`500-
`
`DRL EXHIBIT 1024 PAGE 5
`
`DRL EXHIBIT 1024 PAGE 5
`
`
`
`U.S. Patent
`
`Aug.12, 2008
`
`Sheet 5 of 5
`
`US 7,411,070 B2
`
`7
`
`wn
`nm
`
`25302-Theta-Scale
`
`20
`
`5
`
`cod 10
`
` un
`
`s
`yy
`
`g
`86
`
`~“+°
`
`g gts 8g g.
`RF
`FF F€<R
`|
`BV
`=~
`
`DRL EXHIBIT 1024 PAGE 6
`
`DRL EXHIBIT 1024 PAGE 6
`
`
`
`US 7,411,070 B2
`
`1
`FORM OF S-OMEPRAZOLE
`
`This application is a continuation of U.S. patent applica-
`tion Ser. No. 10/076,711, filed Feb. 14, 2002, now U‘S. Pat.
`No. 6,667,455 whichis a divisional ofU.S. patent application
`Ser. No. 09/077,719, filed Jun. 8, 1998, now U.S. Pat. No.
`6,369,085, which was the National Stage of International
`Application No. PCT/SE98/00974, filed May 25, 1998.
`FIELD OF THE INVENTION
`
`
`
`The present invention relates to a novel form of the (-)-
`enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
`pyridinyl)-methyl|sulfinyl]-1H-benzimidazole,
`i.e. S-ome-
`prazole. More specifically, it relates to a novel form of the
`magnesium salt of the S-enantiomer of omeprazole trihy-
`drate. The present invention also relates to processes for pre-
`paring such a form of the magnesium salt of S-omeprazole
`and pharmaceutical compositions containing it. Furthermore,
`the presentinventionalso relates to intermediates used in the
`process, and their preparation.
`
`PRIOR ART
`
`BACKGROUNDOF THE INVENTION AND
`
`The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-
`2-pyridinyl)methyl|sulfiny!]-1H-benzimidazole, having the
`generic name omeprazole, and therapeutically acceptable
`salts thereof, are described in EP 5129. The specific alkaline
`
`salts of omeprazole are disclosed in EP 124 495. Omeprazole
`is a proton pump inhibitor, i.e. effective in inhibiting gastric
`acid secretion, and is useful as an antiulcer agent. In a more
`general sense, omeprazole may be used for prevention and
`treatment of gastric-acid related diseases in mammals and
`especially in man.
`Omeprazole is a sulfoxide and a chiral compound, wherein
`the sulfur atom being the stereogenic center. Thus, omepra-
`zole is a racemic mixture of its two single enantiomers, the R
`and S-enantiomer of omeprazole, herein referred to as
`R-omeprazole and S-omeprazole. The absolute configura-
`tions ofthe enantiomers of omeprazole have been determined
`by an X-ray study of an N-alkylated derivative of the (+)-
`enantiomer in non-salt form. The (+)-enantiomerof the non-
`salt form and the (—)-enantiomer of the non-salt form were
`found to have R and S configuration, respectively, and the
`(+)-enantiomerofthe magnesium salt and the (—)-enantiomer
`of the magnesium salt were also found to have R and S
`configuration, respectively. The conditions for the optical
`rotation measurement for each of these enantiomers are
`described in WO 94/27988.
`Certainsalts of single enantiomers of omeprazole and their
`preparation are disclosed in WO 94/27988. These compounds
`have improved pharmacokinetic and metabolic properties
`which will give an improved therapeutic profile such as a
`lower degree of interindividual variation.
`WO 96/02535 discloses a process for the preparation ofthe
`single enantiomers of omeprazole andsalts thereof, and WO
`96/01623 discloses a suitable tableted dosage forms of for
`instance magnesium salts of R- and S-omeprazole.
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 shows a X-ray powderdiffractogram of the magne-
`sium salt of S-omeprazole trihydrate prepared according to
`the present invention.
`FIG. 2 shows a X-ray powderdiftractogram ofthe potas-
`sium salt of S-omeprazole prepared and used in the present
`application (See examples 2 and 3)
`
`10
`
`15
`
`20
`
`25
`
`40
`
`45
`
`60
`
`65
`
`2
`FIG. 3 shows a X-ray powder diffractogram of a magne-
`sium salt of S-omeprazole dihydrate prepared and used in the
`present application (See example 5)
`FIG. 4 shows a X-ray powder diffractogram of a magne-
`sium salt of S-omeprazole dihydrate which is a polymorph of
`
`the dihydrate shown in FIG. 3 (See Example 6). This magne-
`sium salt of S-omeprazole dihydrate has been prepared and
`can be used in the preparation of the magnesium salt of
`S-omeprazole trihydrate according to the present invention.
`FIG. 5 shows X-ray powder diffractogram of the magne-
`sium salt of S-omeprazole prepared according to example A
`in WO 96/01623.
`
`DESCRIPTION OF THE INVENTION
`
`Jt has surprisingly been found that the magnesium salt of
`S-omeprazole occurs in a number ofstructurally different
`forms. It is an object of the present invention to provide a
`substantially pure magnesium salt of S-omeprazole trihy-
`drate, hereinafter referred to as the compoundofthe inven-
`tion. This trihydrate can be obtained as a well defined com-
`pound. The present invention also provides a process to
`obtain and a methodofdifferentiating the magnesium salt of
`S-omeprazole trihydrate from other forms of magnesium
`salts of S-omeprazole.
`The compoundofthe invention is advantageous becauseit
`is more stable than the corresponding magnesium salt com-
`poundsinpriorart andis therefore easier to handle andstore.
`The compoundofthe invention is also easier to characterize
`because it exists in a well defined state. Additionally, the
`compoundofthe invention is easier to synthesize in a repro-
`ducible manner and thereby easier to handle in a full scale
`production.
`The magnesium salt of S-omeprazole trihydrate obtained
`according to the present invention is substantially free from
`magnesium salts of R-omeprazole. The magnesium salt of
`S-omeprazole trihydrate obtained according to the present
`invention is also substantially free from other forms of mag-
`nesium salts of S-omeprazole, such as the corresponding
`magnesium salt compounds describedin prior art, and dihy-
`drates used in the preparation of the trihydrate compound
`according to the present invention.
`The compound of the invention is characterized by the
`positions and intensities of the major peaks in the X-ray
`powderdiffractogram, but may also be characterized by con-
`ventional I'T-IR spectroscopy. These characteristics are not
`exhibited by any other form of magnesium salt of S-omepra-
`zole and accordingly, the magnesium salt of S-omeprazole
`trihydrate is easily distinguishable from any other crystal
`form of the magnesium salt of S-omeprazole disclosed in
`prior art. The compoundofthe invention is characterized by
`being highly crystalline, i.e. having a highercrystallinity than
`any other form of magnesium salt of S-omeprazole disclosed
`in the priorart. With the expression “any other form”is meant
`anhydrates, hydrates, solvates, and polymorphs or amor-
`phous formsthereof disclosed in the prior art. Examples of
`any other forms ofmagnesium salt of S-omeprazole includes,
`but are not limited to, anhydrates, monohydrates, dihydrates,
`sesquihydrates, trihydrates, alcoholates, such as methano-
`lates and ethanolates, and polymorphs or amorphous forms
`thereof.
`
`The compound of the invention mayalso be characterized
`by its unit cell.
`In a further aspect, the present invention provides pro-
`cesses for the preparation of the magnesium salt of S-ome-
`prazole trihydrate which comprises;
`
`DRL EXHIBIT 1024 PAGE 7
`
`DRL EXHIBIT 1024 PAGE 7
`
`
`
`US 7,411,070 B2
`
`3
`a) treating a magnesium salt of S-omeprazole of any form,
`for example prepared according is to procedures known
`in the art such as Example A in WO 96/01623 which is
`incorporated herein byreference, with waterat a suitable
`temperature for a suitable time. By a suitable tempera-
`ture is meant a temperature which inducesthe transfor-
`mation of starting material to product without decom-
`posing any of these compounds. Examples of such
`suitable temperatures include, but are not limited to,
`room temperature and above. By a suitable time is meant
`a time that results in high conversion of the starting
`material into product without causing any decomposi-
`tion of either compounds, i.e. results in a good yield.
`This suitable time will vary depending on the tempera-
`ture used in a way well knownto peoplein the art. The
`higher the temperature, the shorter time is needed to give
`the desired conversion. The amount of wateris not cru-
`
`cial and will depend on the process conditions used. The
`magnesium salt of S-omeprazole trihydrateis thereafter
`separated from the aqueousslurry, for example by fil-
`tration or centrifugation and thereafter dried to constant
`weight; or
`b) oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
`pyridinyl)methyl]thio]-1 H-benzimidazole, with an oxi-
`dizing agent and a chiral titanium complex, optionally in
`the presence of a base. The oxidation is carried out in an
`organic
`solvent,
`for example toluene or dichlo-
`romethane.
`
`4
`wheregastric acid inhibitory effect is desirable e.g. in patients
`on NSAIDtherapy, in patients with Non Ulcer Dyspepsia, in
`patients with symptomatic gastro-esophagealreflux disease,
`and in patients with gastrinomas. The compoundofthe inven-
`tion mayalso be used in patients in intensive care situations,
`in patients with acute upper gastrointestinal bleeding, pre-
`and postoperatively to prevent aspiration ofgastric acid and to
`prevent andtreat stress ulceration. Further, the compound of
`the invention maybe useful in the treatment of psoriasis as
`well as in the treatment of Helicobacter infections and dis-
`
`eases related to these. ‘he compound of the invention may
`also be used for treatment of inflammatory conditions in
`mammals, including man.
`Any suitable route of administration may be employed for
`providing the patient with an effective dosage of the magne-
`sium salt of S-omeprazole trihydrate, according to the inven-
`tion. For example, peroral or parental formulations and the
`like may be employed. Dosage formsinclude capsules, tab-
`lets, dispersions, suspensions andthelike.
`It is further provided a pharmaceutical composition com-
`prising the magnesium salt of S-omeprazole trihydrate
`accordingto the invention,as active ingredient, in association
`with a pharmaceutically acceptable carrier, diluent or excipi-
`ent and optionally other therapeutic ingredients. Composi-
`tions comprising other therapeutic ingredients are especially
`of interest in the treatment of Helicobacter infections. The
`
`invention also provides the use of the magnesium salt of
`S-omeprazole trihydrate of the invention in the manufacture
`of a medicament for use in the treatment of a gastric-acid
`related condition and a method of treating a gastric-acid
`related condition which method comprises administering to a
`subject suffering from said condition a therapeutically effec-
`tive amount ofthe magnesium salt of S-omeprazole trihydrate
`according to the invention.
`The compositions of the invention include compositions
`suitable for peroral or parental administration. The mostpre-
`ferred route is the oral route. The compositions may be con-
`veniently presented in unit dosage forms, and prepared by any
`methods knownin the art of pharmacy.
`In the practice of the invention, the most suitable route of
`administration as well as the magnitude of a therapeutic dose
`of the magnesium salt of S-omeprazole trihydrate according
`to the invention in any given case will depend onthe nature
`and severity of the disease to be treated. The dose, and dose
`frequency, may also vary according to the age, body weight,
`and response ofthe individual patient. Special requirements
`may be needed for patients having Zollinger-Ellison syn-
`drome, such as a need for higher doses than the average
`patient. Children and patients with liver diseases generally
`will benefit from doses that are somewhat lower than the
`average. Thus, in some conditions it may be necessary to use
`doses outside the ranges stated below, for example long term
`treatments mayrequest lower dosage. Such higher and lower
`dosesare withinthe scope ofthe present invention. Such daily
`doses may vary between 5 mg to 300 mg.
`In general, a suitable oral dosage form of the compound of
`the invention maycover a dose range from 5 mg to 300 mg
`total daily dose, administered in one single dose or equally
`divided doses. A preferred dosage rangeis from 10 mg to 80
`mg.
`
`The compoundof the invention may be combined as the
`active componentin intimate admixture with a pharmaceuti-
`cal carrier according to conventional techniques, such as the
`oral formulations described in WO 96/01623 and EP 247 983,
`the disclosures of which are hereby incorporated as a whole
`by reference.
`
`‘The crude productis converted to the corresponding potas-
`sium salt by treatment with a potassium source, such as
`methanolic potassium hydroxide or methanolic potassium
`methylate, followed by isolation of the formedsalt.
`The resulting potassiumsalt of S-omeprazole is thereafter
`converted to the corresponding magnesium salt by treatment
`with a magnesium source, such as magnesium sulfate in a
`lower alcohol, such as methanol. Thesolution is optionally
`filtered and the precipitation is initialized by addition of a
`non-solvent such as acetone. The productis filtered off and
`optionally washed with water and further processed as is
`described in a) above. Alternatively, the potassium salt may
`be treated with a magnesium source, such as magnesium
`sulfate in water, and isolation of the magnesium salt of
`S-omeprazoletrihydrate, or any other conventional technique
`for transforming a potassium salt to the corresponding mag-
`nesium salt can be used and is within the scope of the present
`invention.
`Yet a further aspect of the present invention is to provide a
`suitable intermediate used in the preparation ofthe compound
`of the invention, as well as a process for its preparation. The
`potassium salt of S-omeprazole is found to be sucha suitable 5
`intermediate. The potassiumsalt of S-omeprazole may also
`be used as an active component of a pharmaceutical formu-
`lation to be used in the treatment of gastrointestinal discases.
`The compoundofthe invention, i.e. the magnesium salt of
`S-omeprazole trihydrate, prepared according to the present
`invention may be analyzed by XRPD, a technique whichis
`knownperse.
`The amountof water in the magnesium salt of S-omepra-
`zole trihydrate is determined by thermogravimetric analysis,
`a technique which is knownperse.
`The compoundofthe invention is effective as a gastric acid
`secretion inhibitor, and is useful as an antiulcer agent. In a
`more general sense, it can be used for prevention andtreat-
`mentof gastric-acid related conditions in mammals and espe-
`cially in man, including e.g. reflux esophagitis, gastritis,
`duodenitis, gastric ulcer and duodenal ulcer. Furthermore,it
`may be usedfor treatmentof other gastrointestinal disorders
`
`
`
`40
`
`45
`
`60
`
`DRL EXHIBIT 1024 PAGE 8
`
`DRL EXHIBIT 1024 PAGE 8
`
`
`
`US 7,411,070 B2
`
`5
`Combination preparations comprising the magnesium salt
`of S-omeprazole trihydrate and other active ingredients may
`also be used. Examplesof such active ingredients include,but
`are not limited to anti-bacterial compounds, non-steroidal
`anti-inflammatory agents, antacid agents, alginates and pro-
`kinetic agents.
`The examples which follow will further illustrate the
`preparation of the compoundofthe invention, according to
`different process routes and including new intermediates.
`These examples are not intended to limit the scope of the
`invention as defined hereinaboveor as claimed below.
`
`EXAMPLES
`
`Example 1
`
`8-5-methoxy-2-[[(4-methoxy-3,5-dimethy1-2-pyridi-
`nyl)-methy1]sulfinyl]-1H-benzimidazole Magnesium
`Salt Trihydrate
`
`Water (157 kg) was addedto the wet crystals of the mag-
`nesium salt of S-omeprazole, prepared according to Example
`4, below. The mixture was heated to 38° C. with stirring and
`left for 3 hours. The crystals were filtered off and dried in
`vacuo. Yield: 31.6 kg.
`X-ray powder diffraction analysis was performed on a
`sample of the crystals prepared above according to standard
`methods, which can be found in e.g. Kitaigorodsky, A. I.
`(1973), Molecular Crystals and Molecules, Academic Press,
`New York; Bunn, C. W. (1948), Chemical Crystallography,
`Clarendon Press, London; or Klug, H. P. & Alexander, L. E.
`(1974), X-Ray Diffraction Procedures, John Wiley and Sons,
`New York. The analysis gave the diffractogram depicted in
`FIG. 1. The main peaks, with positions andrelative intensi-
`ties, have been extracted from the diffractogram in FIG. 1 and
`is given below in table 1. The relative intensities are less
`reliable and instead of numerical values the following defini-
`tions are used.
`
`% Relative Intensity
`
`Definition
`
`25-100
`10-25
`3-10
`1-3
`<l
`
`vs (very strong)
`s (strong)
`m (medium)
`w (weak)
`vw (very weak)
`
`5
`
`10
`
`20
`
`25
`
`40
`
`45
`
`Some additional very weak peaks found in the diffracto-
`gram have been omitted from table 1.
`
`;
`
`TABLE1
`
`Positions and intensities of the major peaks in the XRP-diffractogram
`of the magnesium salt of S-omeprazole trihydrate.
`
`d-value/A
`2.67
`2.79
`3.27
`3.52
`3.82
`3.96
`4.14
`5.2
`3.6
`6.7
`6.9
`
`Relative Intensity
`
`GRRGooBEB
`
`60
`
`65
`
`6
`
`
`TABLE1-continued
`
`Positions and intensities of the major peaks in the XRP-diffractogram
`of the magnesium salt of S-omeprazole trihydrate.
`
`d-value/A
`8.3
`16.6
`
`Relative Intensity
`w
`vs
`
`Example 2
`
`$-5-methoxy-2-[[(4-methoxy-3,5-dimethy1-2-pyridi-
`nyl)methyl]sulfinyl]-1H-benzimidazole Potassium
`Salt
`
`A solution of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
`pyridinyl)methyl]thio]-1H-benzimidazole
`(15.4
`g, 468
`mmol) in toluene (70 ml) washeated to 50° C. and water (0.05
`ml, 2.8 mmol) and D-(-)-diethyltartrate (2.02 g, 9.82 mmol)
`were added. The reaction mixture was stirred for 20 minutes.
`
`Titanium(IV)isopropoxide (1.34 g, 4.68 mmol) was added
`and the reaction mixture wasstirred for 45 minutes. The
`mixture was cooled to 30° C. and diisopropylethylamine
`(0.91 g, 7.01 mmol) was added followed by cumene hydrop-
`eroxide (9.52 g, 51.89 mmol). The resultant mixture was
`stirred at 30° C. for 3 hours. Methanol (40 ml) was added
`followed by potassium hydroxide (3.05 g, 46.8 mmol) in
`methanol (30 ml). Seed crystals were added andthe reaction
`mixture was stirred at 35° C. overnight. The precipitated
`product wasfiltered off, washed with methanol and toluene
`and dried in vacuo. Yield: 9.74 g (54%).
`
`Example 3
`
`$-5-methoxy-2-[[(4-methoxy-3,5-dimethy1-2-pynidi-
`nyl)-methyl|sulfinyl]-1H-benzimidazole Potassium
`Salt
`
`Water (157.6 pl) was added to a solution of 5-methoxy-2-
`[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-
`benzimidazole in toluene (370 ml; 211.5 g/l) with a water
`content of 0.031% (w/w), followed by addition of D-(-)-
`diethyl tartrate (8.55 ml). The solution was heated to 50° C.
`and stirred at this temperature for 20 minutes. Titantum(IV)
`isopropoxide (7.15 ml) was added andreaction wasleft at 50°
`C. for 45 minutes. The temperature was lowered to 30° C. and
`diisopropylethylamine (6.2 ml) was added. Cumene hydrop-
`eroxide was added at an appropriate speed to maintain the
`temperature from 28° C. to 34° C. The temperature wasraised
`to 35°C. after 2 hours and potassium methoxide (24.55 g) in
`methanol (222 ml) was added. The mixture wasfiltered after
`14 hours and the crystals were washed with methanol:toluene
`(240 ml; 1:1) and methanol (120 ml) and dried. Yield: 79 g
`(74%), ee>99.9%.
`[a]p°°=428.7° (c=1%, water); Assay: 89% is S-5-meth-
`oxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methy]]
`sulfinyl]-1H-benzimidazole potassium salt (11% is metha-
`nol).
`1H-NMR(200 MHz, DMSO-d6, 8 ppm): 2.23 (s, 3H), 2.24
`(s, 3H), 3.71 (s, 3H), 3.75 (s, 3H), 4.40 (d, 1H), 4.78 (d, 1H),
`6.58 (dd, 1H), 7.00 (d, 1H), 7.35 (d, 1H), 8.25 (s, 1H).
`The products from Examples 2 and 3 were analysed using
`X-ray powderdiffraction as described in Example | and gave
`the diffractogram depicted in FIG. 2 and given below in Table
`
`DRL EXHIBIT 1024 PAGE 9
`
`DRL EXHIBIT 1024 PAGE 9
`
`
`
`US 7,411,070 B2
`
`7
`2. Some additional very weak peaks found in the diffracto-
`gram have been omitted from Table 2.
`
`TABLE 2
`
`8
`was added and the resulting mixture wasleft for 4 hours. The
`precipitated product was filtered off, washed with acetone
`and water. The wet crystals were immediately used as is
`described in Example1.
`
`Positions and intensities of the major peaks in the XRP-diffractogram
`of the potassiumsalt of S-omeprazole.
`Relative
`intensity
`
`d-value/A
`» a
`
`
`
`
`
`4 a44443424444224584944445454453SBB4444GReeeBGeeKBHEBES
`
`10
`
`15
`
`20
`
`25
`
`40
`
`45
`
`Example 5
`
`S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridi-
`nyl)-methyl|sulfiny]|-1H-benzimidazole Magnesium
`Salt Dihydrate
`
`5.0 g ofthe moist product from Example 4 with an approxi-
`mate dry content of 74%, was dried in vacuumat 35° C. over
`night to yield 3.58 g (2.68 mmol) of S-5-methoxy-2-[[(4-
`methoxy-3,5-dimethyl-2-pyridinyl)-methy]]sulfinyl]-1H-
`benzimidazole magnesium salt dihydrate, named Form B.
`The product was analyzed using X-ray powderdiffraction
`as described in Example 1, and the analyze gavethe diffrac-
`togram depicted in FIG. 3 and given below in Table 3. Some
`additional peaks with low intensities found in the diffracto-
`gram have been omitted from Table 3.
`
`TABLE3
`
`Positions and intensities of the major peaks in the XRP-diffractogram
`of the magnesium salt of S-omeprazole dihydrate, Form B.
`
`d-value/A
`
`Relative Intensity
`
`SRBRoReRRRabownBRB
`
`Conversion of Magnesium Salt of S-omeprazole Dehydrate
`to Trihydrate
`‘This material was subsequently processed to $-5-methoxy-
`2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methy]]sulfiny]]-
`1H-benzimidazole magnesium salt trihydrate according to
`the procedure described for the moist substance in Example1.
`
`Example 6
`
`$-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridi-
`nyl)-methyl]sulfinyl]-1H-benzimidazole Magnesium
`Salt Dihydrate
`
`A methanolic solution of S-5-methoxy-2-[[(4-methoxy-3,
`5-dimethyl-2-pyridinyl)methy]]sulfinyl]-1 H-benzimidazole
`magnesium salt was prepared as is described in Example 4.
`Such a solution of S-5-methoxy-2-[[(4-methoxy-3,5-dim-
`ethyl-2-pyridinylmethyl]sulfinyl|-1H-benzimidazole mag-
`nesium salt (1.86 g) in 5 ml methanol was concentrated by
`evaporation until 1.58 ml methanol remained. Then, a mix-
`ture of 1.6 ml water and 6.32 ml aceton was added. The
`
`60
`
`65
`
`solution was allowedto crystallize during 26 h at room tem-
`perature. The resulting crystals were filtered off and dried at
`
`al = 1.54060 A
`
`Example 4
`
`S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridi-
`nyl)-methy]]sulfinyl]-1H-benzimidazole Magnesium
`Salt
`
`Methanol (148 kg) was added to S-5-methoxy-2-[[(4-
`methoxy-3,5-dimethyl-2-pyridinylmethyl]sulfiny]]-1H-
`benzimidazole potassium salt
`(71 kg, methanol
`con-
`tent=13%). MgSO,,x7H,0 (40 kg) was added to the mixture
`while stirring. After 70 minutes the mixture wasfiltered and
`the filtrate was washed with methanol (46 kg). The solution
`was concentrated to a volume of 100liter, acetone (253 kg)
`
`DRLEXHIBIT 1024 PAGE 10
`
`DRLEXHIBIT 1024 PAGE 10
`
`
`
`US 7,411,070 B2
`
`9
`40° C. under reduced pressure giving 1.17 g of S-5-methoxy-
`2-[[(4-methoxy-3,5-dimethy1-2-pyridinyl)methyl]|sulfinyl]-
`1H-benzimidazole magnesium salt dihydrate, named form A.
`The product was analyzed using X-ray powderdiffration as
`described in Example 1 and gavethe diffractogram depicted
`in FIG. 4 and given below in Table 4. Some additional peaks
`with low intensities found in the diffractogram have been
`omitted from Table 4.
`
`TABLE4
`
`Positions and intensities of the major peaks in the XRP-diffractogram
`of the magnesium salt of S-omeprazole dihydrate, Form A.
`
`d-value/A
`3.04
`3.14
`3.18
`4.05
`4.19
`4.32
`4.54
`
`Relative Intensity
`
`nnndgunganagaaVS
`
`VS
`
`Example 7
`
`S-5-methoxy-2-[[(4-methoxy-3,5-dimethy1-2-pyridi-
`nyl)-methy]]sulfinyl]-1H-benzimidazole Magnesium
`Salt Trihydrate
`
`10
`of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridiny]l)me-
`thyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was
`added to the magnesium methoxide solution. The mixture
`wasstirred for 12 hours whereupon a small amount of water
`(0.1 ml) was addedin order to precipitate inorganic magne-
`sium salts. After 30 minutesstirring, these inorganic salts
`were filtered off and the solution was concentrated on a
`rotavapor. The residue was now a concentrated methanolic
`solution of the enantiomeric mixture(i.e. the title compound
`contaminated with the (+)-isomer), with an optical purity
`(enantiomeric excess, e.e.) of 80%. ‘This mixture was diluted
`with acetone (100 ml) andafterstirring at room temperature
`for 15 minutes, a white precipitate was obtained. Additional
`suirring for 15 minutes and thereafter filtration afforded 1.3 g
`(50%) ofthe title compound as white crystals. Chiral analyses
`of the crystals and mother liquor were performed by chroma-
`tography on an analytical chiral column. The optical purity of
`the crystals and mother liquor was foundto be 98.4 e.e. and
`64.4% e.e., respectively. Thus, the optical purity (e.e.) has
`been enhanced from 80% to 98.4% simply by crystallizing
`the Mg-salt from a mixture of acetone and methanol. The
`product was crystalline as shown by powder X-ray diffraction
`and the magnesium content was 3.44% as shown by atomic
`absorption spectroscopy. [a],7°=-131.5° (c=0.5%, metha-
`nol).
`The product was analyzed using X-ray powderdiffraction
`as described in Example 1 and gave the diffractogram
`depicted in FIG. 5 and given below in Table 5. Some addi-
`tional very weak peaks foundin the diffractograms have been
`omitted from Table 5.
`
`10
`
`15
`
`20
`
`25
`
`TABLE 5
`
`Positions andintensities of the major peaks
`in the XRP-diffractogram shown in FIG.5.
`
`;
`22.0 g (29,1 mmol) of S-5-methoxy-2-[[(4-methoxy-3,5-
`d-value/A
`Relative Intensity
`dimethy]l-2-pyridinyl)|methyl]sulfinyl]-1H-benzimidazole
`2.90
`s
`potassium salt was dissolved in 40 mL of water. The solution
`3.41
`s
`was seeded with 0.11 g (0,1 mmol) S-5-methoxy-2-[[(4-
`3.90
`8
`methoxy-3,5-dimethyl-2-pyridinyl)-methy]]sulfinyl]-1H-
`4.13
`s
`4.79
`vs
`benzimidazole magnesium salt
`tnhydrate. 22 mL (69,6
`5.00
`vs
`minol) of MgSO, (aq) was added under a 3 h period. The
`5.4
`vs
`slurry wasfiltered off and the precipitate was elutriated in
`5.7
`s
`6.3
`s
`water for approximately 30 minutes and the crystals were
`6.8
`s
`filtered off and dried (35° C., vacuum),
`78
`s
`Yield: 9.15 g (11,6 mmol; 80%). The substance had a
`8.4
`vs
`purity (HPLC):99.8 area %, Mg content: 3.40% (w/w)and ee:
`10.8
`s
`99 8%.
`12.2
`s
`15.1
`vs
`
`40
`
`45
`
`The product was analyzed using X-ray powderdiffraction
`and the result complies with FIG. 1 and Table 1.
`
`Reference Example A
`
`S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridi-
`nyl)-methy]]sulfinyl]-1H-benzimidazole Magnesium
`Salt
`
`(The method used is in accordance with the method
`described in Example A in WO 96/01623)
`Magnesium (0.1 wg, 4.5 mmol) was dissolved and reacted
`with methanol (50 ml) at 40° C. with a catalytic amount of
`methylene chloride. The reaction was run undernitrogen and
`wasfinished after five hours. At room temperature a mixture
`of the two enantiomers [90%(-)-isomer and 10%(+)-isomer]
`
`The invention claimed is:
`
`1. The magnesium salt of S-omeprazole trihydrate.
`2. The magnesium salt of S-omeprazole trihydrate accord-
`ing to claim 1 represented by FIG. 1.
`3. A process for the preparation of the magnesium salt of
`S-omeprazole trihydrate according to claim 1 which com-
`prises treating a magnesium salt of S-omeprazole of any other
`form with water.
`
`4. A process for the preparation of the magnesium salt of
`S-omeprazole trihydrate according to claim 2 which com-
`prises treating a magnesium salt of S-omeprazole of any other
`form with water.
`
`DRL EXHIBIT 1024 PAGE 11
`
`DRL EXHIBIT 1024 PAGE 11
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ ChargeStill Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site